The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
AAN 2025 | Updated guidelines for the treatment of RLS by the American Academy of Sleep Medicine
Ambra Stefani, MD, PhD, Medical University of Innsbruck, Innsbruck, Austria, comments on the updated guidelines for restless legs syndrome (RLS) by the American Academy of Sleep Medicine. She highlights recommendations against the use of levodopa and dopaminergic agents due to the risk of augmentation. Conditional recommendations are also made for new treatments such as dipyridamole and peroneal nerve stimulation. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For restless legs syndrome there are international guidelines by the International Restless Legs Syndrome Study Group which are still current but there are also more recent guidelines by the American Academy of Sleep Medicine published a few months ago and the main change there is that because of the augmentation which is this paradoxical reaction to treatment, mainly dopaminergic treatment, there is for the first time a conditional recommendation against the use of levodopa and also dopaminergic agents which still can be used if patients put more relevance into the short-term effect of medication compared to the long term...
For restless legs syndrome there are international guidelines by the International Restless Legs Syndrome Study Group which are still current but there are also more recent guidelines by the American Academy of Sleep Medicine published a few months ago and the main change there is that because of the augmentation which is this paradoxical reaction to treatment, mainly dopaminergic treatment, there is for the first time a conditional recommendation against the use of levodopa and also dopaminergic agents which still can be used if patients put more relevance into the short-term effect of medication compared to the long term. And this is because of the risk of augmentation which is really high and then it’s really difficult to treat. And other news are also conditional recommendation for dipyridamole and also for the peroneal nerve stimulation which are new treatments let’s say based on available studies but that is a new indication for RLS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
